How we diagnose and treat essential thrombocythaemia.
In: British Journal of Haematology, Jg. 171 (2015-11-01), Heft 3, S. 306-322
academicJournal
Zugriff:
The approach to the diagnosis and management of essential thrombocythaemia ( ET) is steadily changing, influenced by advances in molecular biology, data from clinical trials and retrospective analyses of patient cohorts. In the past decade options for clinical management largely remain unchanged, but who we treat, and with what target in mind, is evolving. A further area of change is recognition of symptoms that may be associated with ET, as well as other myeloproliferative neoplasms, and that potential options for their management are becoming available. Judicious and careful diagnosis is increasingly a fundamental key to successful management followed by cytoreductive therapy in a subset of patients. In this review we demonstrate our management strategies for ET using a case-based format. [ABSTRACT FROM AUTHOR]
Titel: |
How we diagnose and treat essential thrombocythaemia.
|
---|---|
Autor/in / Beteiligte Person: | Alimam, Samah ; Wilkins, Bridget S. ; Harrison, Claire N. |
Zeitschrift: | British Journal of Haematology, Jg. 171 (2015-11-01), Heft 3, S. 306-322 |
Veröffentlichung: | 2015 |
Medientyp: | academicJournal |
ISSN: | 0007-1048 (print) |
DOI: | 10.1111/bjh.13605 |
Schlagwort: |
|
Sonstiges: |
|